Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA045153 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA045153, RRID:AB_10797259
- Product name
- Anti-PRAME
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human PRAME, Gene description: preferentially expressed antigen in melanoma, Alternative Gene Names: CT130, MAPE, Validated applications: WB, Uniprot ID: P78395, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Preferentially expressed antigen in melanoma as a novel diagnostic marker differentiating thymic squamous cell carcinoma from thymoma
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens
PRAME expression and promoter hypomethylation in epithelial ovarian cancer
Impact of Preferentially Expressed Antigen of Melanoma on the Prognosis of Hepatocellular Carcinoma
PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas
Taniguchi Y, Ishida M, Saito T, Ryota H, Utsumi T, Maru N, Matsui H, Hino H, Tsuta K, Murakawa T
Scientific Reports 2020;10(1)
Scientific Reports 2020;10(1)
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens
Chang A, Dao T, Gejman R, Jarvis C, Scott A, Dubrovsky L, Mathias M, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson R, Liu C, Scheinberg D
Journal of Clinical Investigation 2017;127(7):2705-2718
Journal of Clinical Investigation 2017;127(7):2705-2718
PRAME expression and promoter hypomethylation in epithelial ovarian cancer
Zhang W, Barger C, Eng K, Klinkebiel D, Link P, Omilian A, Bshara W, Odunsi K, Karpf A
Oncotarget 2016;7(29):45352-45369
Oncotarget 2016;7(29):45352-45369
Impact of Preferentially Expressed Antigen of Melanoma on the Prognosis of Hepatocellular Carcinoma
Oyama K, Kanki K, Shimizu H, Kono Y, Azumi J, Toriguchi K, Hatano E, Shiota G
Gastrointestinal Tumors 2016;3(3-4):128-135
Gastrointestinal Tumors 2016;3(3-4):128-135
PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Field M, Decatur C, Kurtenbach S, Gezgin G, van der Velden P, Jager M, Kozak K, Harbour J
Clinical Cancer Research 2016;22(5):1234-1242
Clinical Cancer Research 2016;22(5):1234-1242
The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas
Nettersheim D, Arndt I, Sharma R, Riesenberg S, Jostes S, Schneider S, Hölzel M, Kristiansen G, Schorle H
British Journal of Cancer 2016;115(4):454-464
British Journal of Cancer 2016;115(4):454-464
No comments: Submit comment
No validations: Submit validation data